Both genetic and pharmacological USP22 inhibition largely reduced the breast cancer stem cell pool through down-regulating integrin b1, also known as CD29, a cell surface glycoprotein that is critical in almost every step of cancer progression, including cancer initiation, proliferation, local invasion, and metastatic colonization of the new tissue 18, 19. This evidence concerns the gene ITGB1 and cancer.